Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Oswald Burkhard"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kohlbrenner, Katharina *, Galuschek, Norbert *, Fabarius, Alice *, Reiser, Marcel *, Fenchel, Klaus *, Eßeling, Eva *, Göhler, Thomas *, Geer, Thomas *, Depenbusch, Reinhard *, Azeh, Ivo Talah *, Engel, Erik *, Hansen, Richard *, Lindemann, Hans-Walter *, Anhuf, Jürgen *, Jehner, Paul *, Abu-Samra, Maisun *, Ritter, Markus *, Gattermann, Norbert, Pelz, Henning *, Fuxius, Stefan *, Oswald, Burkhard *, Baerlocher, Gabriela M, Brummendorf, Tim H.H., Heim, Dominik *, le Coutre, Philipp, Burchert, Andreas, Niederwieser, Dietger, Tesch, Hans *, Hofmann, Wolf-Karsten, Hochhaus, Andreas, Hehlmann, Rüdiger, Saussele, Susanne
Publikováno v:
In Blood 15 November 2022 140 Supplement 1:947-949
Autor:
C van Roye, R Weide, B Rendenbach, Stefan Feiten, Jochen Heymanns, Julia Lutschkin, Peter Ehscheidt, Hubert Köppler, Jörg Thomalla, Kristina Kleboth, U Braun, H-P Laubenstein, Vera Friesenhahn, K Hünermund, Oswald Burkhard, Geothy Chakupurakal
Publikováno v:
Cancer Research. 79:P1-16
Introduction: 18,000 women die due to metastatic breast cancer in Germany per year. Median survival is 20–28 months after diagnosis. The question we wanted to answer was whether survival has improved in routine care? Methods: Retrospective analysis
Autor:
Johannes Meiler, Victor Rodriguez-Laval, Steffen Heeg, Anja A. Kühl, Ruza Arsenic, Ulrich-Frank Pape, Karel Caca, Stefan Kasper, Holger Jansen, Arndt Vogel, Oswald Burkhard, Petra Büchner-Steudel, Marianne Sinn, Peter Treasure, Nalân Utku, Lothar Müller
Publikováno v:
Cancers
Volume 12
Issue 11
Cancers, Vol 12, Iss 3149, p 3149 (2020)
Volume 12
Issue 11
Cancers, Vol 12, Iss 3149, p 3149 (2020)
CAP7.1 is a novel topoisomerase II inhibitor, converted to active etoposide via carboxylesterase 2 (CES2), with signals of efficacy in treatment-refractory solid tumours. In a Phase II trial, 27 patients with advanced biliary tract cancers (BTC) were
Autor:
Richard A. Hansen, John Strehl, Stefan Feiten, Oswald Burkhard, Rudolf Weide, Michael Maasberg, Joachim Behringer, Peter Ehscheidt, Monika Grundheber, Bernhard Rendenbach
Publikováno v:
Applied Cancer Research, Vol 37, Iss 1, Pp 1-8 (2017)
Background The aim of this study was to assess retrospectively treatment and outcome of CML-patients in community based oncology practices in Germany and whether European LeukemiaNET (ELN) recommendations were followed. Method All Ph+, BCR-ABL1+ CML-
Autor:
Concetta Laliscia, Stefan Feiten, Emanuela Parietti, Gabriele Calaminus, Ines Cafaro, Oliver Rick, Monika Reuss-Borst, Ulf Seifart, Oswald Burkhard, Bernhard Wörmann, Eva-Maria Kalusche-Bontemps, Timm Dauelsberg, Amelia Barcellini, Ali Montazeri, Desiree Grabow, Mario Miniati, Fabiola Paiar, Shahpar Haghighat, Maria Grazia Fabrini, Davide Baldaccini, Jan Schmielau, Rudolf Weide, Diana Steinmann, Riccardo Morganti, Alipasha Meysami, Angiolo Gadducci, Thorsten Langer, Marcel Reiser, Peter Ehscheidt, Geothy Chakupurakal, Monika Steimann, Hossein Yari, Druck
Publikováno v:
Oncology Research and Treatment. 40:816-820
Autor:
Ulrich-Frank Pape, Oswald Burkhard, Nalan Utku, Karel Caca, Steffen Heeg, Ruza Arsenic, Lothar Mueller, Marianne Sinn, Anya A Kühl, Johannes Meiler, Holger Jansen, Arndt Vogel, Victor Rodriguez Laval, Stefan Kasper
264 Background: The novel drug EDO-S7.1 (CAP7.1) is converted to active etoposide by CES allowing administration of higher doses, reducing resistance, and permitting treatment of advanced tumors. Methods: The primary objective was to compare disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9884cad576c01a7ea15c3ebf4032cc29
Autor:
Stefan Feiten, Geothy Chakupurakal, Marcel Reiser, Rudolf Weide, Oswald Burkhard, Peter Ehscheidt
Publikováno v:
Oncology research and treatment. 40(12)
Background: Randomized clinical trials do not reflect the day-to-day reality of patient care; hence, the treatment of patients with advanced pancreatic cancer in oncology group practices was evaluated. Patients and Methods: All consecutive patients w
Autor:
Marianne Sinn, Nalan Utku, T. Mehrling, Anja A. Kühl, Johannes Meiler, V. Rodriguez Laval, Ruza Arsenic, Karel Caca, Holger Jansen, S. Heeg, K. Hilgier, Arndt Vogel, Oswald Burkhard, Ulrich-Frank Pape, Stefan Kasper, Lothar Mueller, I. Wagner
Publikováno v:
Annals of Oncology. 30:v278
Background Etoposide toniribate (also known as EDO-S7.1, and previously known as CAP7.1), a novel topoisomerase II inhibitor, is activated in the presence of carboxylesterases. In specific tumor cell lines, it was found to be more active than etoposi
Autor:
Ulrike Bacher, Torsten Haferlach, Britta Bechtel, Claudia Haferlach, Wolfgang Kern, Tamara Weiss, Oswald Burkhard, Susanne Schnittger
Publikováno v:
Cancer Genetics and Cytogenetics. 200:170-174
Reciprocal IGH/14q32 translocations are detectable in 55-70% of patients with plasma cell myeloma; e.g., the adverse t(4;14)(p16;q32) fusing the IGH and FGFR3 genes (immunoglobulin heavy chain/fibroblast growth factor receptor 3). In a minority of pa